Spotlight: Time To Buy Vaccine Manufacturer Before Winter?
It’s impossible to discuss Moderna without mentioning its COVID-19 vaccine, which propelled the stock to record highs in 2021 approaching $500 per share. However, slower sales caused the stock to plunge by almost 80%.
Second-quarter reports in 2023 show a net loss of $1.38 billion, a stark contrast to the net income of $5.4 billion in Q4 2021.
» Read more about: Spotlight: Time To Buy Vaccine Manufacturer Before Winter? »